eConsult wins contract with Homerton Emergency Department to help reduce waiting times
eConsult have won a contract to implement their eTriage system in Homerton Emergency Department to enable an electronic check-in service.
eConsult have won a contract to implement their eTriage system in Homerton Emergency Department to enable an electronic check-in service.
Calculus EIS, VCT and Creative Content EIS portfolio company today released the Devil’s Advocate: The Mostly True Story of Giovanni Di Stefano, on Sky and NowTV.
Maze Theory shares held by Calculus Capital EIS Funds and the Calculus VCT plc have been purchased by a strategic investor, Pluto Digital
The essence of eConsult is to ask the questions ahead of the consultation. We gather information 24 hours a day, at the patient’s convenience
Important note: Performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Co-head of investments Richard Moore recently spoke to Wealth Club about Calculus and our VCT offering.
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. By Oliver Warren, Investor Relations Associate In the 21/22 tax year, £1.13bn was invested in VCTs*, a record amount and a more than impressive show of … Continued
The story behind Wonderhood’s new documentary featured in The Telegraph. He is known as the ‘Devil’s Advocate’, and rarely can there have been a more deliciously appropriate epithet. In a legal career that seemingly knew no bounds, Giovanni di Stefano claimed to have offered counsel to Osama bin Laden, Saddam Hussein, Slobodan Milošević, Arkan, Robert … Continued
Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to … Continued
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our final quarterly update of 2021. This has been a record-breaking year for Calculus as we have delivered 11 exits and over £50million back to … Continued
By Matthew Moynes, Assistant Director of Investor Relations, Calculus Capital Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Synonymous with UK venture capital investing is the attractive tax incentives provided by HMRC which help … Continued